Product category:
Polymerase chain reaction (PCR)
News Release from: Qiagen | Subject: HiPerFect
Edited by the Laboratorytalk Editorial
Team on 12 October 2005
Collaborating with Curie on
high-throughput RNAi
Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project
The BioPhenics project, led by Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery "As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous
This article was originally published on Laboratorytalk on 17 Feb 2005 at 8.00am (UK)
Related stories
Highly efficient siRNA transfection and silencing
Transfection reagent combines high transfection efficiency and low cytotoxicity, allowing effective transfection of primary cells
The goal of the BioPhenics project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery" said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.
"Qiagen is pleased to be able to contribute to this ambitious and exciting research" said Jie Kang, VP of R and D at Qiagen.
"The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.".
• Qiagen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
